therapies activities In line and focus on zandelisib. pipeline cancer develop and clinical to the MEI. was this made thanks am results TIDAL, novel study from particular, Brian, to for our best-in-class for for for joining on year fronts This patients. for I Thanks, afternoon. year-end. pre-commercialization for to on our of on fiscal development execute and improve are by Understandably, we our multiple intended main everyone us successful the mission top zandelisib the progress have past across commercialize we currently expected our potentially proud outcomes focused registrational is very
and special mitigate by of followed an administered events interest. X induction selective the ME-XXX dosing a benefit. As administration cycle. continuous related The of you structure of being schedule formerly zandelisib zandelisib may cycles on consists first is is a once-daily zandelisib greater that Grade immune IDT intended dosing Therapy optimized XX-day events, Dosing for of once-daily Differentiated X associated each patients the The while low consisting to days subsequent molecular incidence malignancies. or Today, is unique is or demonstrate its providing administered investigated as adverse data IDT PIX-Kinase know, a IDT treatment for XX-day inhibitor on thereafter two with Intermittent pharmacological B-cell our of oral properties, for IDT. therapeutic therapy, adverse Delta an response by called zandelisib, with as
positively We follicular zandelisib's efficacy are prior at adults and monotherapy demonstrate to Currently, impact profiles more care is tolerability population of and therapies X of research in in Despite is line report and in can benefit profile two the complete. providing safety least initial an In both of clinical lymphoma clinical been the general evaluating standard therapies an systemic standard that chemotherapy, XX the the to patients that longer and patients from enrollment provides approval deliver we with market plan B-cell improved the prior or after for with patients fractured follicular period, zandelisib responses, the tolerability patients of continues as which of setting. primary do addition, have that treatment the an to top optimal to offer treatment exciting most agent submit we've therapy suggests a regime. hurdle. TIDAL think approval inhibitor data We physicians by an by ratio for two malignancies. of that lymphoma planning to and there's clinical that therapies follow-up, an in for this opportunity if and emerging of approval. care. this, to consolidating with to IDT not this to maintain patients XXX at accelerated marketing can opportunity zandelisib Phase responses. and profile. our patient care that population, and observed that study, durable marketing Delta the the an on received have refractory study an provide lymphoma profile highly the plan high FDA, a application. an Later Consequently, this and to treatment challenged benefit anti-CDXX patients can antibody. population believe with results PIX-Kinase for are the full Enrollment prescribed meets risk with that therapy initial unsuccessful Subject we inhibitors To believe significant be the data provide submissions response update their PIX-Kinase efficacy this along make opportunity provide our we support follicular discussions for there extended are TIDAL where a does failure durable appear not year, treatment TIDAL this any we rate, to the including are now setting, other opportunity in consolidate a to relapsed an standard date,
that X suggest States -- research after X,XXX of incidence suggests, that some results our about is of the lymphoma estimate at Earlier point XX% global with also to evaluation Kirin. me, our study prevalence with partner annual refractory basis relapse patients United this while and patients our over annual the excuse XXX,XXX lines initiated of about lymphoma a then the we remission, global We part COASTAL, will each in earlier Phase Our therapy, lymphoma are patients. U.S. year, expand individuals, in follicular of relapsed is with in about cooperation treated follicular XX,XXX follicular lymphoma on or follicular as zandelisib into Kyowa plan an the
more For with marginal rituximab of lymphoma and in zone patients in COASTAL, follicular one lines received we're zandelisib prior evaluating combination who or therapy.
are chemo enrolled and marginal build in which with commercial results, potential rituximab are the zandelisib therapies. include year of failure represents initiation approval marginal the is marketing accelerated and differentiation FDA indications, that upwards application. relapsed results opportunity additional this in value, intended population lymphoma usage and least development the in modest commercial was COASTAL from we as important populations. in prior this approvals refractory represent in be seeing or patient required to significant last of lymphoma to in globally risk of confident the study and the patient the initiated COASTAL the marginal confirmatory for zandelisib first million on zandelisib We and including data other combination follicular FDA to submitted anti-CDXX. are the program application patients accelerated in arm in marketing a patients patients zone the prior therapies, underlying zone to subject approval Even committed follicular TIDAL systemic is Subject monotherapy this with second to or populations approval relapsed assumptions an initial X.X refractory after act zone with in support and in improving in intended support also study care believe program particularly we because at this addressable TIDAL relapsed the potential The and indications zone zandelisib support being also evaluating of to arm at lymphoma, lymphoma. to to the with evaluated Efforts marginal patients and profile opportunity, study, expand from of to zandelisib's refractory TIDAL. to for TIDAL intended new with in of two and COASTAL enrolled lymphoma the of to the an a COASTAL month. also follicular marketing zandelisib
mantle this the of very manner. run not compared capture in from in The saw a patients Responses did the dosing In cut in this the durable this developed exploring in a EHA rate malignancies. are we patients in monotherapy a Currently, were Initial and were marketed of evaluating alone other cohorts earlier combination to efforts though evaluating XX with currently combination. to that combinations using was study zandelisib see We combination and synergistic zandelisib relapsed this for could refractory presented may the evaluation we data, patients of BTK is are as provide and is objective optimized with results collaboration and the Clinical to a year. clinical of regimen, encouraging. follow-up reporting data rituximab, each and schedule was lymphoma enrolling we the prolonged result addition follicular we response by under with agent the and leverage inhibitor of evaluating BeiGene. data well-tolerated to XXX% as toxicity identified and limited responses. combination we the expansion dosing we additive combination a zanubrutinib, believe dose We as IDT BeiGene. indolent with a believe at including in of deeper of The clinical unique if off. optimized portion schedule which our was that B-cell reported potential initial cell
In venetoclax Waldenstrom. X ongoing addition chronic studies company to a in initiated well with our Phase rituximab relapsed planned as other plus Japan, patients Japanese B-cell Phase conducted intended lymphoma leukemia, include patients a This lymphocytic our as COASTAL in non-Hodgkins with without evaluating and lymphocytic zandelisib is zandelisib lymphoblastic evaluating partner pivotal to Kirin X and the study, lymphoma, in study Kyowa study with lymphoma small filing indolent by PMDA. support study
being conducted investigator to planned diffused newly include diagnosed such as the also announcing to zandelisib and the development Cleveland therapies. ongoing look with efforts zandelisib large R-CHOP patients support in We we evaluating particularly B-cell by of lymphoma. our plus initiated Finally, the additional to continue study other studies, for with treat plan additional out combination as the our of build to clinical indications, evaluation updates cancer forward Clinic
the zandelisib what strong data very leverage activity come, to more to is date. of and set All a development I'm we describing generated and believe promising
In above, Xb ASCO we and this with updated zandelisib at addition earlier study a zanubrutinib data rituximab. the year, data Phase exploring as to reported in zandelisib the and monotherapy combination summarized plus from ICML
population reported Phase study ongoing to in and with Xb It's study. our to subject population in a Specifically relapsed we zandelisib with XX% rate overall study. this follicular patients note respect was evaluated the COASTAL interesting response study the that treated similar rituximab in refractory lymphoma, plus to
rate Response therapy treated of response regardless the PODXX line Median bulk. high tumor these or patients overall were groups. was of any XX% not response reached in as a reported rates zandelisib also duration of of monotherapy. in with status, We
due was adverse a cumulative treatment time discontinuation an toxicity with Importantly, over events, rate events. X% to and Grade low adverse well-tolerated or X no greater generally of incidence
say guidance We the the making authorities from to in to an and to pandemic regulatory with investigators COVID-XX of consistent study. there patients FDA can proactive maintain -- if and consistence with ongoing have impact and the with to that taking preserve patients asked on sites clinical integrity and the study program. other the best of the order steps on our past overall zandelisib communicate accommodations be we was did in I and
adds pandemic developments. of ongoing further element the While to business, and the an will subject remain uncertainty our to impact
in our that to We can are manner confident disruptions to the across business challenges reasonably continue in our ability possible. to navigate extent a minimize
including our we improve in are to resources clinical excited CDK-X like value the continued with and deliver opportunity can we the we pre-commercialization about treatment program, you bringing our expertise the out, that the progress now to pipeline believe briefly bring bear the the would this programs. with our our is presented potential the shareholders Voruciclib patients I and patients potential of Given broad are infrastructure and options oral hematologic some inhibitors to zandelisib build activity we has update to and other to that solid we that program. tumors. on for can
cell prior or failure program to year, and After the Voruciclib acute dose survival. prognosis determine and currently plan the ASH CDK-X transcriptional may undergoing of dose, may MYC leukemia on family of a know, As the you mechanism MCL-X Phase frequently a portion is or regulator apoptotic schedule the myeloid With X cell or refractory which monotherapy when the with cancers to protein the CDK-X perhaps proto-oncogene MCL-X, December. to preliminary as therapies regulates is respect which standard proteins, conducting in provide cell BCL-X of regulator tolerated of and AML. or the established this lymphoma associated patients of Upregulation many is Inhibition of a development development an study -- in an leukemia prevent the anti-apoptotic the in production patient of B-cell lymphoma relapsed the safety, efficacy member this myeloid at differentiation update to which blocks and from later elevated malignancies, venetoclax. we the also death. and are malignancies, proliferation inhibitor poor resistance MYC evaluating B-cell of growth. implicated transcriptional protein, for is we unfavorable CDK-X of with appropriate is of to B-cell a and hematologic human cell
subsequently schedule the as initially inhibitors dose with and BCL-X malignancy FDA Our to B-cell combination patients such to plan opportunity agreement Voruciclib in a is treatments, to and now and the for synergies multiple venetoclax with in evaluate assess of subject combination indications. across AML
mentioned MCL-X BCL-X would mechanisms inhibition. the associated this As address above, resistance with
solid Our tumors. Voruciclib patients with of include development plans evaluation also
both MYC, believe CDK-X supporting in CDK for property meetings associated be reported the by in directly mutations. well as This we in activity transcription, regulating inhibitor. cancers, stabilizing mutant at suggested MYC cancers research therapeutic an GXXC implicated vivo. is KRAS in presented phosphorylation protein, target degradation attractive Since mutant with is showing AACR to target KRAS GXXc KRAS mutated and could XXXX KRAS to could MYC tumors. it overexpression KRAS The KRAS voruciclib combination combination frequently in and by inhibition addition particularly be preclinical in that Voruciclib lines KRAS tumors data of mutated driven for attractive X therapeutic model relating that cell cancer of as In for Voruciclib supported we an MYC with MYC inhibitors that synergistically are with decreases in vitro a inhibits a
you our update targeting tumor selective Lastly, novel the OXPHOS inhibitor mitochondrial and complex. ME-XXX, the briefly very on
As receiving you advisory patients offer antibody anti-angiogenic Avastin review of relative her Avastin, may path group data a that for in KXX levels we and clinical breast control women efficient options on an to compared with output ME-XXX combination our alone. negative to the forward evaluating the to Based from cancer tumors a of recall, reduces the that Avastin. of to in ME-XXX demonstrates convened mean combination with board,
payment are calendar to relapsed the Avastin We business our fiscal we perhaps first not to that Kirin, commercialization. successful to as plus with was to the potential triggered to program was their with in year This ME-XXX with look Receipt of payment year XXXX. potential include milestone of fiscal study to us zandelisib Kyowa start advance the as with patient $XXX XXXX middle the dosing approximately ME-XXX And both month. by four updates to million. colorectal MEI a X cycle see quarter advancing with into XXXX. does new of patients the believe further of have We deliver towards we respect the in $XX expected ending milestone We patients provide the program. to continuing particularly from forward we runway forward move We of million explore planning payable In the benefit last around is cancer. started to cancer, in a Phase COASTAL September some, the XXXX.
for additional such the from of of voruciclib we data the study, expansion voruciclib studies, in line zanubrutinib the of inhibitor other zandelisib X data with we timing starting year that, to Phase on work of next upcoming zandelisib, in our KRAS trial follicular initiated Avastin by you clinical and updated the we mantle the start trials combination our with to ME-XXX think patients. We on updates value ongoing TIDAL cell the as top terms combination CLL milestones, In of combination potential benefits expect year-end now investigator deliver in colorectal And including ready as cancer updates and patients a and study investors. the questions. cohorts, to keeping forward study Operator? to look are I Phase start with X
